Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease.

Verstockt B, Verstockt S, Dehairs J, Ballet V, Blevi H, Wollants WJ, Breynaert C, Van Assche G, Vermeire S, Ferrante M.

EBioMedicine. 2019 Feb;40:733-742. doi: 10.1016/j.ebiom.2019.01.027. Epub 2019 Jan 24.

2.

Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response.

Dreesen E, Van Stappen T, Ballet V, Peeters M, Compernolle G, Tops S, Van Steen K, Van Assche G, Ferrante M, Vermeire S, Gils A.

Aliment Pharmacol Ther. 2018 Feb;47(3):346-355. doi: 10.1111/apt.14452. Epub 2017 Dec 11.

3.

PR3-anti-neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis.

Mahler M, Damoiseaux J, Ballet V, Dillaerts D, Bentow C, Cohen Tervaert JW, Blockmans D, Boeckxstaens G, Aguilera-Lizarraga J, Csernok E, Vermeire S, Bossuyt X.

Clin Chem Lab Med. 2017 Nov 27;56(1):e27-e30. doi: 10.1515/cclm-2017-0346. No abstract available.

PMID:
28755529
4.

Chromoendoscopy versus narrow band imaging in UC: a prospective randomised controlled trial.

Bisschops R, Bessissow T, Joseph JA, Baert F, Ferrante M, Ballet V, Willekens H, Demedts I, Geboes K, De Hertogh G, Vermeire S, Rutgeerts P, Van Assche G.

Gut. 2018 Jun;67(6):1087-1094. doi: 10.1136/gutjnl-2016-313213. Epub 2017 Jul 11.

PMID:
28698230
5.

Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease.

Billiet T, Cleynen I, Ballet V, Claes K, Princen F, Singh S, Ferrante M, Van Assche G, Gils A, Vermeire S.

Scand J Gastroenterol. 2017 Oct;52(10):1086-1092. doi: 10.1080/00365521.2017.1339825. Epub 2017 Jun 16.

PMID:
28622097
6.

Effects of introduction of an inflammatory bowel disease nurse position on the quality of delivered care.

Coenen S, Weyts E, Vermeire S, Ferrante M, Noman M, Ballet V, Vanhaecht K, Van Assche G.

Eur J Gastroenterol Hepatol. 2017 Jun;29(6):646-650. doi: 10.1097/MEG.0000000000000839.

PMID:
28118176
7.

Effects of Education and Information on Vaccination Behavior in Patients with Inflammatory Bowel Disease.

Coenen S, Weyts E, Jorissen C, De Munter P, Noman M, Ballet V, Vermeire S, Van Assche G, Ferrante M.

Inflamm Bowel Dis. 2017 Feb;23(2):318-324. doi: 10.1097/MIB.0000000000001013.

PMID:
28079621
8.

Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment.

Wauters L, Billiet T, Papamichael K, Ballet V, Joniau S, Verschueren P, Silversmit G, Van Assche G, Vermeire S, Ferrante M.

Eur J Gastroenterol Hepatol. 2017 Jan;29(1):84-90.

PMID:
27603297
9.

Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experience.

Billiet T, Cleynen I, Ballet V, Ferrante M, Van Assche G, Gils A, Vermeire S.

Aliment Pharmacol Ther. 2016 Oct;44(7):673-83. doi: 10.1111/apt.13754. Epub 2016 Aug 9.

10.

Comprehensive in vitro Proarrhythmia Assay (CiPA): Pending issues for successful validation and implementation.

Cavero I, Guillon JM, Ballet V, Clements M, Gerbeau JF, Holzgrefe H.

J Pharmacol Toxicol Methods. 2016 Sep-Oct;81:21-36. doi: 10.1016/j.vascn.2016.05.012. Epub 2016 May 24. Review.

PMID:
27233533
11.

Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD.

Sabino J, Vieira-Silva S, Machiels K, Joossens M, Falony G, Ballet V, Ferrante M, Van Assche G, Van der Merwe S, Vermeire S, Raes J.

Gut. 2016 Oct;65(10):1681-9. doi: 10.1136/gutjnl-2015-311004. Epub 2016 May 20.

12.

Identifying predictors of low adherence in patients with inflammatory bowel disease.

Coenen S, Weyts E, Ballet V, Noman M, Van Assche G, Vermeire S, Van Emelen J, Ferrante M.

Eur J Gastroenterol Hepatol. 2016 May;28(5):503-7. doi: 10.1097/MEG.0000000000000570.

PMID:
26760588
13.

Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study.

Cleynen I, Van Moerkercke W, Billiet T, Vandecandelaere P, Vande Casteele N, Breynaert C, Ballet V, Ferrante M, Noman M, Assche GV, Rutgeerts P, van den Oord JJ, Gils A, Segaert S, Vermeire S.

Ann Intern Med. 2016 Jan 5;164(1):10-22. doi: 10.7326/M15-0729. Epub 2015 Dec 8.

PMID:
26641955
14.

Thromboembolism as an important complication of inflammatory bowel disease.

Bollen L, Vande Casteele N, Ballet V, van Assche G, Ferrante M, Vermeire S, Gils A.

Eur J Gastroenterol Hepatol. 2016 Jan;28(1):1-7. doi: 10.1097/MEG.0000000000000495.

PMID:
26513610
15.

Smoking behaviour and knowledge of the health effects of smoking in patients with inflammatory bowel disease.

De Bie C, Ballet V, Hendriks N, Coenen S, Weyts E, Van Assche G, Vermeire S, Ferrante M.

Aliment Pharmacol Ther. 2015 Dec;42(11-12):1294-302. doi: 10.1111/apt.13423. Epub 2015 Oct 4.

16.

Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease.

Lobatón T, Ferrante M, Rutgeerts P, Ballet V, Van Assche G, Vermeire S.

Aliment Pharmacol Ther. 2015 Aug;42(4):441-51. doi: 10.1111/apt.13294. Epub 2015 Jun 24.

17.

Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.

Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, Simoens S, Rutgeerts P, Gils A, Vermeire S.

Gastroenterology. 2015 Jun;148(7):1320-9.e3. doi: 10.1053/j.gastro.2015.02.031. Epub 2015 Feb 24.

PMID:
25724455
18.

Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease.

Drobne D, Bossuyt P, Breynaert C, Cattaert T, Vande Casteele N, Compernolle G, Jürgens M, Ferrante M, Ballet V, Wollants WJ, Cleynen I, Van Steen K, Gils A, Rutgeerts P, Vermeire S, Van Assche G.

Clin Gastroenterol Hepatol. 2015 Mar;13(3):514-521.e4. doi: 10.1016/j.cgh.2014.07.027. Epub 2014 Jul 25.

PMID:
25066841
19.

A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis.

Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, Ballet V, Claes K, Van Immerseel F, Verbeke K, Ferrante M, Verhaegen J, Rutgeerts P, Vermeire S.

Gut. 2014 Aug;63(8):1275-83. doi: 10.1136/gutjnl-2013-304833. Epub 2013 Sep 10.

PMID:
24021287
20.

Metabolic profiling of the impact of oligofructose-enriched inulin in Crohn's disease patients: a double-blinded randomized controlled trial.

De Preter V, Joossens M, Ballet V, Shkedy Z, Rutgeerts P, Vermeire S, Verbeke Phd K.

Clin Transl Gastroenterol. 2013 Jan 10;4:e30. doi: 10.1038/ctg.2012.24.

21.

Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.

Van Assche G, Vermeire S, Ballet V, Gabriels F, Noman M, D'Haens G, Claessens C, Humblet E, Vande Casteele N, Gils A, Rutgeerts P.

Gut. 2012 Feb;61(2):229-34. doi: 10.1136/gutjnl-2011-300755. Epub 2011 Sep 23.

PMID:
21948942
22.

Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy.

Schnitzler F, Fidder H, Ferrante M, Ballet V, Noman M, Van Assche G, Spitz B, Hoffman I, Van Steen K, Vermeire S, Rutgeerts P.

Inflamm Bowel Dis. 2011 Sep;17(9):1846-54. doi: 10.1002/ibd.21583. Epub 2011 Jan 6.

PMID:
21830263
23.

Effect of oligofructose-enriched inulin (OF-IN) on bacterial composition and disease activity of patients with Crohn's disease: results from a double-blinded randomised controlled trial.

Joossens M, De Preter V, Ballet V, Verbeke K, Rutgeerts P, Vermeire S.

Gut. 2012 Jun;61(6):958. doi: 10.1136/gutjnl-2011-300413. Epub 2011 Jul 11. No abstract available.

PMID:
21749983
24.

Effects of haptoglobin polymorphisms and deficiency on susceptibility to inflammatory bowel disease and on severity of murine colitis.

Márquez L, Shen C, Cleynen I, De Hertogh G, Van Steen K, Machiels K, Perrier C, Ballet V, Organe S, Ferrante M, Henckaerts L, Galicia G, Rutgeerts P, Ceuppens JL, Vermeire S.

Gut. 2012 Apr;61(4):528-34. doi: 10.1136/gut.2011.240978. Epub 2011 Jun 27.

PMID:
21708824
25.

Identification of a novel autoantigen in inflammatory bowel disease by protein microarray.

Vermeulen N, de Béeck KO, Vermeire S, Van Steen K, Michiels G, Ballet V, Rutgeerts P, Bossuyt X.

Inflamm Bowel Dis. 2011 Jun;17(6):1291-300. doi: 10.1002/ibd.21508. Epub 2010 Oct 25.

PMID:
21560193
26.

Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study.

Breynaert C, Ferrante M, Fidder H, Van Steen K, Noman M, Ballet V, Vermeire S, Rutgeerts P, Van Assche G.

Am J Gastroenterol. 2011 Apr;106(4):778-85. doi: 10.1038/ajg.2011.61. Epub 2011 Mar 15.

PMID:
21407184
27.

Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease.

Jürgens M, Mahachie John JM, Cleynen I, Schnitzler F, Fidder H, van Moerkercke W, Ballet V, Noman M, Hoffman I, van Assche G, Rutgeerts PJ, van Steen K, Vermeire S.

Clin Gastroenterol Hepatol. 2011 May;9(5):421-7.e1. doi: 10.1016/j.cgh.2011.02.008. Epub 2011 Feb 17.

PMID:
21334460
28.

Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment.

Vande Casteele N, Ballet V, Van Assche G, Rutgeerts P, Vermeire S, Gils A.

Gut. 2012 Feb;61(2):321; author reply 322. doi: 10.1136/gut.2010.236869. Epub 2011 Feb 17. No abstract available.

PMID:
21330576
29.

Seroreactivity against glycolytic enzymes in inflammatory bowel disease.

Vermeulen N, Vermeire S, Arijs I, Michiels G, Ballet V, Derua R, Waelkens E, Van Lommel L, Schuit F, Rutgeerts P, Bossuyt X.

Inflamm Bowel Dis. 2011 Feb;17(2):557-64. doi: 10.1002/ibd.21388.

PMID:
20629101
30.

The isolated rabbit heart and Purkinje fibers as models for identifying proarrhythmic liability.

Roche M, Renauleaud C, Ballet V, Doubovetzky M, Guillon JM.

J Pharmacol Toxicol Methods. 2010 May-Jun;61(3):238-50. doi: 10.1016/j.vascn.2010.01.011. Epub 2010 Feb 1.

PMID:
20117224
31.

A low frequency of lymph node metastasis in clear-cell renal cell carcinoma is related to low lymphangiogenic activity.

Baldewijns MM, Roskams T, Ballet V, Van den Eynden GG, Van Laere SJ, Van der Auwera I, Lerut E, De Bruïne AP, Thijssen VL, Vermeulen PB, van Poppel H.

BJU Int. 2009 Jun;103(12):1626-31. doi: 10.1111/j.1464-410X.2008.08272.x. Epub 2009 Jan 12.

Supplemental Content

Loading ...
Support Center